COLON CANCER

Advisers to the U.S. Food and Drug Administration on Thursday recommended for the approval of Guardant Health’s blood test to detect a cancer that begins in the colon or rectum. The panel voted seven-to-two in favor of benefits outweighing risks when using the test called Shield for colorectal cancer. If approved, Shield could become the second blood-based…